NCT07217717 - Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Pancreatic Ductal Adenocarcinoma (PDAC) | Biotech Hunter

Enrollment

200

Participants

Timeline

Start Date

December 15, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions

Pancreatic Ductal Adenocarcinoma (PDAC)

Interventions

DRUG

[18F]FAPI-74 PET/CT

\[18F\]FAPI-74 is a radioactive diagnostic agent indicated for use with Positron Emission Tomography (PET) imaging for the detection of Fibroblast Activation Protein (FAP) positive cancer cells and cancer-associated fibroblasts (CAF) in patients with pancreatic ductal adenocarcinoma.